If you're researching GLP-1 medications for weight loss, you've probably landed on the same question everyone asks: tirzepatide or semaglutide — which one is better? The honest answer is nuanced, but the clinical data gives us a lot to work with. Let's break it down.

The Fundamental Difference: Single vs. Dual Agonist

Understanding why these drugs produce different results starts with their mechanisms:

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. It mimics the natural GLP-1 hormone, activating one receptor pathway. This slows gastric emptying, reduces appetite, improves insulin sensitivity, and acts on brain centers that regulate food intake and reward. For a detailed breakdown of this mechanism, see our article on how GLP-1 medications work.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone involved in insulin secretion, fat metabolism, and appetite regulation. By hitting both targets, tirzepatide produces effects through two complementary pathways.

Think of it this way: semaglutide presses one accelerator pedal. Tirzepatide presses two. That doesn't automatically make it "better" — it makes it different, and for most outcomes, more potent.

The Weight Loss Numbers: SURMOUNT vs. STEP

The fairest comparison uses the pivotal trials for each drug's weight loss indication:

STEP 1 (Semaglutide 2.4mg)

  • 1,961 participants, 68 weeks
  • Mean weight loss: -14.9%
  • Participants losing ≥20%: 32%

SURMOUNT-1 (Tirzepatide, highest dose 15mg)

  • 2,539 participants, 72 weeks
  • Mean weight loss at 15mg: -20.9%
  • Participants losing ≥20%: 57%
  • At 10mg: -19.5%; at 5mg: -15.0%

The headline difference: at the highest doses, tirzepatide produced roughly 6 percentage points more weight loss than semaglutide. For someone starting at 240 lbs, that's the difference between losing about 36 lbs (semaglutide) and 50 lbs (tirzepatide). That's clinically significant.

However, cross-trial comparisons have limitations. These trials had different participant populations, slightly different durations (72 vs 68 weeks), and different inclusion criteria. The only way to truly compare is a head-to-head randomized trial — and we now have one.

SURPASS Trials: Tirzepatide vs. Semaglutide Head-to-Head

The SURPASS-2 trial directly compared tirzepatide to semaglutide 1mg (the diabetes dose, not the 2.4mg weight loss dose) in patients with type 2 diabetes over 40 weeks.

Results:

  • Tirzepatide 15mg: -12.4 kg (~27 lbs)
  • Tirzepatide 10mg: -11.2 kg (~25 lbs)
  • Tirzepatide 5mg: -7.8 kg (~17 lbs)
  • Semaglutide 1mg: -5.7 kg (~13 lbs)

At all three doses, tirzepatide significantly outperformed semaglutide 1mg for both weight loss and glycemic control (HbA1c reduction). However, this comparison isn't entirely fair — semaglutide 1mg is a lower dose than the 2.4mg used for weight management. A head-to-head of tirzepatide 15mg vs. semaglutide 2.4mg would be more informative, and such trials are ongoing.

Based on the available evidence, most obesity medicine specialists estimate that tirzepatide at maximum dose produces approximately 5-8% greater weight loss than semaglutide at maximum dose in comparable populations. For the full breakdown of semaglutide trial data, see our dedicated analysis.

Side Effect Profiles: Broadly Similar, Some Differences

Both medications share the same primary side effect: gastrointestinal symptoms. Nausea, vomiting, diarrhea, and constipation are common with both, particularly during dose escalation. For a comprehensive guide to managing these, see our article on GLP-1 side effects.

Semaglutide (from STEP trials)

  • Nausea: 44% (vs 18% placebo)
  • Diarrhea: 30% (vs 16% placebo)
  • Vomiting: 24% (vs 6% placebo)
  • Constipation: 24% (vs 11% placebo)
  • Discontinuation due to adverse events: 7.0%

Tirzepatide (from SURMOUNT-1)

  • Nausea: 24-33% (dose-dependent, vs 10% placebo)
  • Diarrhea: 18-23% (vs 8% placebo)
  • Vomiting: 8-13% (vs 2% placebo)
  • Constipation: 17-20% (vs 4% placebo)
  • Discontinuation due to adverse events: 4.3-7.1%

At first glance, tirzepatide appears to have somewhat lower rates of nausea and vomiting, though direct comparisons are tricky across different trials. The GIP agonism in tirzepatide may have a slightly protective effect against nausea, though this isn't definitively established.

Both drugs carry the same rare but serious risk warnings: pancreatitis, gallbladder disease, and (in animal studies) thyroid C-cell tumors. These risks appear comparable between the two medications based on current data.

Dosing and Titration

Semaglutide (Wegovy): Injected weekly. Titration over 16-20 weeks: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg. Each dose level is held for 4 weeks.

Tirzepatide (Zepbound): Injected weekly. Titration over 16-28 weeks: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Each dose level is held for 4 weeks, with more dose options allowing finer titration.

Tirzepatide's additional dose levels (six vs. five for semaglutide) give prescribers more flexibility. If a patient responds well at 10mg without intolerable side effects, they can stay there rather than being pushed to a higher dose. This granularity can help balance efficacy and tolerability.

Cost Comparison

As of early 2025, the list prices are roughly comparable:

  • Wegovy (semaglutide 2.4mg): ~$1,350/month list price
  • Zepbound (tirzepatide): ~$1,060/month list price
  • With insurance: Highly variable — $0 to $500+/month depending on plan
  • Through telehealth providers: Compounded versions of both are available at significantly lower prices (often $200-500/month)

Insurance coverage varies significantly. Some plans cover one but not the other, or cover them only for specific diagnoses (type 2 diabetes vs. obesity). For a detailed comparison of the brand names and their approved uses, see our medication comparison guide.

Who Might Prefer Which?

Tirzepatide might be preferred when:

  • Maximum weight loss is the primary goal
  • The patient has type 2 diabetes (strong dual glucose-lowering effect)
  • Previous GI intolerance to semaglutide (may tolerate tirzepatide better)
  • More granular dose titration is desired

Semaglutide might be preferred when:

  • Cardiovascular risk reduction is important (SELECT trial data — no equivalent exists yet for tirzepatide)
  • Longer safety track record is valued (semaglutide has been on the market longer)
  • Insurance covers Wegovy but not Zepbound
  • Oral formulation is desired (oral semaglutide exists; no oral tirzepatide yet)

The Bottom Line

If weight loss is the sole metric, tirzepatide has the edge — approximately 5-8% greater body weight reduction at maximum doses. But "better" depends on more than peak weight loss. Cardiovascular data, insurance coverage, side effect tolerance, prescriber experience, and individual response all factor in.

Many patients try one and switch to the other based on their response. Some obesity medicine clinics now use tirzepatide as first-line for patients with higher BMI (where maximum weight loss matters most) and semaglutide for patients with cardiovascular disease or established CVD risk factors.

The good news: both drugs produce clinically significant weight loss that was unimaginable a decade ago. Whether you lose 15% or 21% of your body weight, you're looking at a transformation that meaningfully improves health, appearance, and quality of life.

Want to see what that level of change looks like on you? The MeOnGLP tool projects your transformation using clinical data ranges — try it to visualize your projected results in 60 seconds.